Cuál es el precio por Clarus Therapeutics Holdings, Inc. (CRXTQ)

Precio por Clarus Therapeutics Holdings, Inc. (CRXTQ) es de$0.0014

Cuál es la capitalización de mercado por Clarus Therapeutics Holdings, Inc. (CRXTQ)

Capitalización de mercado por Clarus Therapeutics Holdings, Inc. (CRXTQ) es $72.83K

Clarus Therapeutics Holdings, Inc. (CRXTQ) Desdoblamientos de Acciones

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

Año	Desdoblamiento	Multiplicador	Multiplicador acumulado
Not enough data for the provided dates.

Año

Desdoblamiento

Multiplicador

Multiplicador acumulado

Not enough data for the provided dates.

Empresa	Número de desdoblamientos de acciones	Multiplicador acumulado	País
Eli Lilly and Company LLY.US	4	x15	US
Johnson & Johnson JNJ.US	7	x432	US
AbbVie Inc. ABBV.US	0	-	US
Roche Holding AG RO.SW	2	x10000	CH
Merck & Co., Inc. MRK.US	7	x226	US

Empresa

Número de desdoblamientos de acciones

Multiplicador acumulado

País